Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H₃ receptor antagonist

Shuichi Terasakaa Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, JapanCorrespondence[email protected]

Kenji Hachiumaa Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan

Yoko Manob Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan

Koichi Onishib Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan

Iwao Kitajimab Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan

Izumi Nishinob Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan

https://orcid.org/0000-0002-7754-1986

Hiromi Endoa Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan

show all

Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H₃ receptor antagonist

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H3 receptor antagonist

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H₃ receptor antagonist